Victory Capital Management Inc. Boosts Stock Position in Balchem Co. (NASDAQ:BCPC)

Victory Capital Management Inc. grew its holdings in shares of Balchem Co. (NASDAQ:BCPC) by 4.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,031 shares of the basic materials company’s stock after buying an additional 1,788 shares during the period. Victory Capital Management Inc. owned 0.13% of Balchem worth $6,625,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in BCPC. Norges Bank acquired a new position in Balchem in the fourth quarter valued at approximately $52,233,000. APG Asset Management US Inc. acquired a new position in shares of Balchem in the 4th quarter valued at $39,164,000. Corient Private Wealth LLC grew its position in shares of Balchem by 4,678.4% in the 4th quarter. Corient Private Wealth LLC now owns 262,671 shares of the basic materials company’s stock valued at $39,072,000 after buying an additional 257,174 shares during the last quarter. Vanguard Group Inc. raised its stake in Balchem by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company’s stock worth $609,873,000 after acquiring an additional 144,423 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Balchem by 32.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 193,146 shares of the basic materials company’s stock valued at $29,929,000 after acquiring an additional 47,036 shares during the last quarter. 87.91% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Balchem

In other Balchem news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $180.05, for a total value of $1,395,387.50. Following the transaction, the senior vice president now directly owns 8,540 shares of the company’s stock, valued at approximately $1,537,627. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BCPC. HC Wainwright lifted their target price on Balchem from $170.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. StockNews.com lowered Balchem from a “buy” rating to a “hold” rating in a research report on Monday, July 29th.

Balchem Trading Up 2.2 %

Shares of Balchem stock opened at $171.82 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83. The company has a market capitalization of $5.57 billion, a P/E ratio of 48.54, a PEG ratio of 5.18 and a beta of 0.65. Balchem Co. has a 1 year low of $110.74 and a 1 year high of $186.03. The company’s fifty day moving average is $170.34 and its two-hundred day moving average is $158.62.

Balchem (NASDAQ:BCPC) last released its quarterly earnings results on Friday, July 26th. The basic materials company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The firm had revenue of $234.08 million for the quarter, compared to analyst estimates of $241.26 million. Balchem had a return on equity of 10.94% and a net margin of 12.52%. Analysts forecast that Balchem Co. will post 3.96 earnings per share for the current year.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.